Department of Diagnostic and Interventional Radiology, Aichi Cancer Center Hospital, 1-1, Kanokoden, Chikusa-ku, Nagoya, Aichi, 464-8681, Japan.
Department of Radiology, Shiga University of Medical Science, Otsu, Shiga, Japan.
Clin J Gastroenterol. 2024 Apr;17(2):286-291. doi: 10.1007/s12328-024-01921-2. Epub 2024 Feb 11.
Herein, we report the successful treatment using atezolizumab plus bevacizumab of a patient with hepatocellular carcinoma (HCC) with a portal vein tumor thrombus and multiple pulmonary metastases from rectal cancer with microsatellite stability. This patient developed rectal cancer with synchronous pulmonary metastases and HCC. After resecting the primary lesion of the rectal cancer, transcatheter arterial chemoembolization was performed for the HCC. Drug therapy was planned for multiple pulmonary metastases of rectal cancer; however, the early development of recurrent HCC with portal vein tumor thrombus had to be highly prioritized, and atezolizumab plus bevacizumab was introduced. Following the disappearance of the recurrent HCC lesion, the metastatic pulmonary nodules shrunk into scar-like spots. The treatment for both HCC and pulmonary metastases of rectal cancer were considered to result in clinical complete response.
在此,我们报告了一例成功的治疗案例,一名结直肠癌合并微卫星稳定的肝细胞癌(HCC)患者,其存在门静脉癌栓和多发肺转移。该患者同时患有直肠癌合并肺转移和 HCC。在切除直肠癌的原发灶后,对 HCC 进行了经导管动脉化疗栓塞。直肠癌的多发肺转移计划进行药物治疗,但 HCC 伴门静脉癌栓的早期复发需要高度优先处理,因此引入了阿替利珠单抗联合贝伐珠单抗。在复发性 HCC 病变消失后,转移性肺结节缩小成瘢痕样斑点。HCC 和结直肠癌的肺转移治疗均被认为达到了临床完全缓解。